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Spitz nevus, also called spindle and epithelioid cell nevus or ‘‘juvenile
melanoma,’’ is a benign neoplasm of epidermal melanocytes. Its histologic
appearance is occasionally difficult to distinguish from that of tumorigenic
malignant melanoma of the nodular type [1–3]. The cells of a Spitz nevus are
both spindled and epithelioid in form and characteristically migrate from the
epidermis in an invasive pattern that often extends deep into the dermis.
Histologic features that tend to distinguish Spitz nevi from nodular melanomas
include their generally smaller size, symmetry, circumscription, maturation of
the lesional cells with descent into the dermis, and characteristically low mitotic
rate without abnormal mitoses [4]. Nodular melanomas, however, can be quite
small and symmetrical, and there may be overlap between the two lesions in
features such as dermal invasion, mitotic activity, cellular atypia, and maturation
patterns. Analytical criteria that have been found to have limited diagnostic
utility in this important differential diagnosis have included morphometric
analysis [5,6], DNA analysis [7–9], and silver staining of nucleolar organizer
regions [10–15]. In addition, several immunohistochemical analyses of
melanoma-associated antibodies have been performed on small numbers of
Spitz nevi. Only a few such antibodies have been tested because, in general, the
pertinent antigens are destroyed in formalin-fixed, paraffin-embedded tissue.
Because Spitz nevi are available almost exclusively in paraffin blocks, antibodies
whose antigens survive processing must be used for immunophenotyping. The
few such antibodies tested have not shown specific diagnostically distinctive
qualitative staining pattern differences between Spitz nevi and melanomas
[8,16–21]. Potentially useful quantitative differences have been reported in one
study for S-100 and neuron-specific enolase expression levels determined by
image analysis [8]. We used a panel of monoclonal antibodies (MoAbs) against
antigens that survive routine tissue processing to phenotype a series of Spitz
nevi, compound nevi, and vertical growth-phase (tumorigenic) melanomas.
Most of these antigens have not been previously evaluated in Spitz nevi.
MATERIALS AND METHODS
Characteristic examples of 16 Spitz nevi, 15 compound nevi, and 20 malignant
melanomas with vertical growth phase were chosen randomly from patient files in
the Section of Dermatopathology, Hospital of the University of Pennsylvania. The
specimens had been received for pathologic diagnosis in formalin and routinely
processed into paraffin blocks. None of the Spitz or compound nevi had a
microscopically dysplastic component. The melanomas were all in vertical growth
phase, either Clark’s level III or IV [22].
For immunohistochemistry, 5-mm sections were cut, placed on Staon-coated
slides (Surgipath, Grayslake IL), and dried in a 40 1C oven for 1–2h. The slides were
then deparaffinized and hydrated in a series of graded alcohols followed by
phosphate-buffered saline (PBS). Endogenous peroxidase within the tissues was
blocked by incubation of the slides in 0.3% H2O2 in PBS for 30min at room
temperature (RT), followed by two 10-min rinses in PBS. Non-specific binding sites
were then blocked by dilute horse serum for 20min at room temperature (Vectastain
avidinbiotin complex kit, anti-mouse immunoglobulin (Ig) G peroxidase, Vector Labs,
Burlingame, CA). Antibodies were then applied to slides in a humidified chamber and
incubated overnight in a 4 1C refrigerator. On the second day, the slides were washed
in PBS, incubated again in dilute horse serum for 10min, incubated for 1 h at RT with
horse anti-mouse biotinylated antibody, washed with PBS, and incubated for 1 h at RT
with avidin-peroxidase complex (all from the Vectastain kit). The tissues were then
rinsed well with PBS and incubated for 13min with aminoethylcarbazole chromogen
as the peroxidase substrate (Vector Labs). The slides were then rinsed well in distilled
water, counterstained with Mayer’s hematoxylin, rinsed in tap water, and mounted
with aqueous mounting medium.
Eleven antibodies were selected from preliminary studies because of their specific
reactivity with melanocytic lesions in paraffin sections. MoAbs ME491, ME121,
ME109, and ME23 were raised against formalin-fixed, paraffin-embedded melanoma
cell lines and tested against paraffin-embedded tissues [23]. MoAb ME121 recognizes
an 80-kDa protein. MoAbME23 binds to a proteoglycan antigen, the molecular weight
of which has not been determined. MoAb ME 109 is a protein antigen identified as
both 72 and 90kDa [24]. MoAb ME 491 recognizes a 30–60-kDa highly glycosylated
protein that may be related to melanosomal and/or lysosomal membranes (CD63) [25].
MoAb 404 is a highly glycosylated 30–50-kDa protein antigen with homology to the
antigen recognized by MoAbs ME491 and NKI/C3. MoAb ME67-6 was raised to a
crude ganglioside fraction and recognizes a 50–70-kDa heavily glycosylated antigen
with a 20–30-kDa core protein. Disulfide bridges appear to provide intrachain stability.
The immunizing preparation for this antibody was a crude ganglioside fraction, but
recent work suggests that the antigen is probably not strictly associated with
gangliosides. MoAb 506 binds to the highly glycosylated 30–60-kDa protein originally
defined by MoAb ME491. Antibodies NKI/C3 [19] and HMB-45 [26] were purchased
commercially (Bio-genex, San Ramon, CA). MoAb ME325 recognizes a 110-kDa
protein and neutral lipid antigen, whereas MoAb MEJC1 binds to a 90-kDa antigen
(M. Herlyn and A. Menrad, unpublished observations). Antibodies were used either as
undiluted supernatants (MoAbs ME67-6, 506, ME325, MEJC1,404), or were titrated
from ascites and used at a dilution of 1:1000 (MoAbs ME491, ME121, ME109, ME23).
MoAbs NKI/C3 and HMB-45 were used without further dilution. A murine myeloma
MoAb P3x63Ag8 was used as a negative control antibody on each specimen, and
positive internal controls were confirmed with each antibody run. Antibodies were of
the IgG 1, IgG2a, or IgG2b class. Sections were initially evaluated by a single observer
(BL) with review of a subset of cases by two observers (BL and DE). Staining was
evaluated as negative or ± to 3þ , depending on intensity, with ± very light or
equivocal staining. The percentage of positive cells within each specimen was
assessed overall, and in addition the percentages of reactive cells in the upper,
middle, and lower thirds of each lesion were assessed separately (to assess
‘‘stratification’’ of reactivity; Figs 1 and 2). Lesions were assessed as positive with a
given antibody if 5% or more of the cells reacted at an intensity of 1þ or greater.
Results were also expressed as the average percentage of cells reacting at intensity of
1þ or greater in each lesional group. Statistical analysis was done using a package
for microcomputers (Systat, Inc, Evanston IL).
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RESULTS
Reactivity of Lesions Five of the antibodies (ME491, NKI/C3, 506, ME67-6, and
404) reacted strongly with all four categories of pigmented lesions (Table I). No
statistically significant differences were found in reactivity among the lesional
classes. These five antibodies did show a tendency to differential reactivity in
that they bound in a stratified pattern within the dermal component of
compound nevi but not Spitz nevi or melanomas (see below).
Four of the antibodies (ME121, ME23, ME109, and HMB-45) showed
statistically significant differences in reactivity among the three lesional
categories [compound nevi, Spitz nevi, and melanomas (Table I, Fig 3)]. On
the basis of the percentage of lesions reacting (Table I) as well as the average
percentage of positive cells in each lesional category (Fig 3), the reactivity of
Spitz nevi with MoAbs ME121 and ME23 resembled that of compound nevi
and was significantly greater reactivity than that of melanomas (po0.05 and
o0.01 respectively, for Spitz nevi versus melanoma). Conversely, the reactivity
of Spitz nevi with MoAb ME109 resembled that of melanoma and differed from
that of compound nevi (po0.01). With the HMB-45 antibody, the reactivity of
Spitz nevi was intermediate between a low rate of expression in compound
nevi and a higher rate in melanoma (Table I, Fig 3). The reactivity of Spitz nevi
was significantly different from that of compound nevi, but the difference from
melanoma was not significant (po0.02, Fig 3; po0.05, Table I). MoAb ME325
did not show significant differences among the groups, and MoAb MEJC1 was
reactive in only a small percentage of cases (Table I).
Stratification of Reactivity Within Lesions Table II shows staining patterns
observed within the four lesional categories categorized in terms of the
reactivity of four antibodies in the upper, middle, and lower third of the
lesions. These antibodies (ME491, NKI/C3, 506, and ME67-6) showed a
tendency to stratify from the upper to lower portion of the dermal component
of compound nevi, typically demonstrating reduced expression at deeper
levels with predominant reactivity in the upper third. The antigen distribution
in Spitz nevi was different from that in compound nevi with these antibodies.
Most of the Spitz nevi showed diffuse and/or patchy antigen distribution,
patterns that resembled those seen in the melanomas. A second group of Spitz
nevi showed a reversal of the staining pattern that was usual in compound
nevi, with progressive acquisition of antigens rather than loss in the lowest
third of the dermal component, best seen with antibodies ME491 and 506
(Table II). In general, melanomas tended to show diffuse or patchy distribution
of these antigens, with no tendency to stratification within the dermis. In a few
cases, the upper third or upper and lower third of the dermal component
showed staining predominance. The staining patterns in melanoma were
more heterogeneous than in compound nevi, tending to be diffuse or patchy
in antigen distribution, with no consistent pattern of acquisition or loss of
antigens. Spitz nevi occupied an intermediate position in this regard (Table II).
DISCUSSION
The antigenicity of Spitz nevi was previously investigated only to a limited
extent because of the destruction of many melanoma-associated antigens in
the process of fixation and paraffin embedding. We used a panel of 11 MoAbs
that bind to ‘‘nevomelanoma antigens’’ on archival material. In skin, several
of these antigens appear to be highly expressed in the junctional and
superficial dermal melanocytic zones of common compound nevi and Spitz
nevi and to be more diffusely distributed in melanomas, suggesting that they
may be markers that are preferentially expressed in immature, active, or
proliferating lesional cells.
All of the antibodies bind to antigens that are expressed to some degree in
a variety of melanocytic lesions. They all survive fixation and embedding and
do not react with normal melanocytes in paraffin-embedded skin biopsies.
Many of these antigens, however, are present in other normal and neoplastic
tissue types. ME67-6, 506, ME121, ME109, and ME23 in this study showed
some low-level binding to adnexal structures, such as sweat and sebaceous
gland, and occasionally to squamous epithelium (Fig 2). MoAbs ME491,
ME67-6, and NKI/C3 bind to macrophages. MoAbs NKI/C3 and ME491 have
Figure 1. Immunoreactivity of compound nevus with MoAb 67-6. Paraffin
section stained with mouse MoAb 67-6 using avidin-biotin immuno-
peroxidase technique and aminoethyl carbazole chromogen. Red reaction
product is concentrated in upper third of lesion, a ‘‘stratified’’ reaction pattern
(see text).
Figure 2. Immunoreactivity of Spitz nevus with MoAb 67-6. Reaction pattern
is ‘‘diffuse,’’ with uniform intense staining of a majority of the lesional cells in
the upper, middle, and lower thirds of the lesion.
314S LAZZARO ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
been reported to react with a number of other epithelial tumor types [27,28];
the related MoAb 404 has not been studied in as much detail. MoAb HMB-45
shows high specificity for junctional nevic cells and melanoma [29], but
reactivity has been reported in the dermal cells of dysplastic nevi [30], in blue
nevi [31], and in several non-melanocytic tissues when certain ascites
preparations are used [32].
Antibodies Exhibiting Differential Patterns of Reactivity Among Whole
Lesions Four of the antibodies evaluated in this study (ME121, ME23, ME109,
and HMB-45) showed statistically significant differential reactivity for
compound nevi, Spitz nevi, and/or vertical growth-phase melanomas. These
antibodies also tended not to show notable maturation-associated stratifica-
tion in common nevi.
Spitz nevi differed from melanoma and resembled compound nevi in their
expression of two of the five antigens, those recognized by MoAbs ME121 and
ME23 (Fig 3). These two antibodies thus appear to recognize nevus-associated
antigens that might, for example, play some role in maturation or
differentiated cell function. Spitz nevi resembled melanoma and differed
from compound nevi in expression of two other antigens, those of MoAbs ME
109 and HMB-45 (Fig 3). Like the HMB-45 antibody, the ME109 antibody
shows an affinity for junctional melanocytes in nevi and melanomas, as well
as a variable number of nevic and melanoma cells in the dermis. Binding in
the dermal cells of compound nevi is low and infrequent, significantly
different from the higher levels of binding in Spitz nevi and melanomas
(Fig 3). HMB-45 is present in the junctional component of common
compound nevi but generally not in the dermis; dermal cells of some
dysplastic nevi, Spitz nevi, and melanomas express the antigen in varying
degrees [18]. These two antigens may be associated with some attribute
shared by the dermal cells of Spitz nevi and melanomas, such as proliferative
capacity or invasiveness.
These data suggest that Spitz nevi express some antigenic properties more
likely to be associated with compound nevi and some more likely to be
associated with melanomas. Collectively, Spitz nevi appear to take a position
between compound nevi and melanomas with this panel of antibodies. This
finding may explain the difficulties in efforts to raise Spitz-specific MoAbs for
diagnostic purposes that do not cross-react with melanoma. Antibodies ME23
Table I. Reactivity of Melanocytic Lesions [n positive/n tested (%)]
Antibody Antigen
Compound
Nevi
p
value
Spitz
Nevi
p
value
Melanoma Vertical-Growth
Phase
Broadly reactive antibodies
ME 491 30–60-kDa glycoprotein (CD63) 15/15 (100) NSa 15/16 (94) NS 20/20 (100)
NKI-C3 25–110-kDa, homologous with ME49.1 15/15 (100) NS 15/16 (94) NS 18/20 (90)
506 30–60-kDa glycoprotein cross-reactive with
CD63
15/15 (100) NS 15/15 (100) NS 18/19 (95)
ME67-6 50–70-kDa glycoprotein 15/15 (100) NS 14/15 (93) NS 17/18 (94)
404 30-50-kDa cross-reactive with CD63 14/15 (93) NS 8/16 (50) NS 15/20 (75)
Nevus-associated antibodies
ME121 80-kDa protein 5/15 (33) NS 8/15 (53) o0.05 4/19 (21)
ME23 Proteoglycan 6/15 (40) NS 10/15 (66) o0.01 4/20 (20)
ME121+ and ME23+ 5/15 (33) o0.05 1/19 (5)
ME121 ME23, and
HMB45+
4/15 (27) o0.05 13/19 (68)
Melanoma-associated antibodies
HMB-45 Not characterized 2/15 (14) o0.01 8/16 (50) NS 16/20 (80)
ME109 92/70-kDa protein 2/15 (13) o0.0112/16 (75) NS 11/20(55)
Weakly reactive antibodies
ME325 110-kDa protein and neutral lipid 4/15 (27) NS 5/15 (33) NS 7/19 (37)
MEJC1 90 kDa 2/15(13) NS 3/16 (19) NS 3/20 (15)
aNS, no significant difference between adjacent columns.
Figure 3. Antigenic reactivity of common nevi, Spitz nevi, and nodular
melanomas (NM). Box plots show the distribution of values for the percentage
of cells reacting with antibodies ME23, ME109, ME121, and HMB-45.
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and ME121 could be used in combination as a diagnostic test with 95%
specificity for Spitz nevus versus melanoma (Table I); however, this degree of
specificity coupled with the low sensitivity of 33% would not be of much use in
clinical practice. Adding HMB-45 reactivity to the ‘‘panel’’ does not improve the
utility of the test (Table I).
Nevomelanocyte Marker and Maturation-Associated Antibodies Five of the
antigens evaluated in this study, those recognized by MoAbs ME491, NKI/C3,
506, 404, and ME67-6, were markers of melanocytic lineage cells, reacting
with all four categories of pigmented lesions. These antigens were markers for
nevocytic immaturity as well, in that reactivity in common nevi tended to be
more prominent superficially, disappearing in the lower dermis where nevic
cells are more mature. Spitz nevi and melanomas were less likely to show this
‘‘stratification of antigenic reactivity,’’ tending to stain diffusely when
positive. Some Spitz nevi and a few melanomas had a tendency to stratify
and acquire antigens in the deep dermis in a direction opposite to that of
compound nevi.
Stratification of cell types in nevi has been described previously by
traditional light microscopy, by image analysis including DNA analysis, and
by immunohistochemistry. By traditional light microscopy, the dermal cells of
compound or dermal nevi have been divided into superficial larger
epithelioid and often pigmented type A cells; intermediate, usually non-
pigmented cuboidal type B cells; and deeper spindled type C cells. The latter
cell type corresponds to the ‘‘neurotized’’ nevus cell. Histochemically, these
cells are positive for cholinesterase, a neural marker and negative for the
melanocytic marker tyrosinase [33]. By immunohistochemistry, the type C but
not type A or B cells are positive with the Schwann cell marker AHMY1 [34],
although negative for myelin basic protein, myelin-associated protein, and
glial fibrillary acidic protein [35]. Paul et al [36] studied 39 melanocytic nevi
for S-100 antigen and three melanoma-associated antigens and reported
stratification of reactivity with antibodies BM24-2, NKI/C3, Mel-1, and Mel-2
reacting most prominently with the superficial type A cells. One antibody,
34.1, reacted with deeper type C cells [36]. The data presented here confirm
the stratification of NKI/C3 and add four other examples of stratified antigens
in compound nevi. Although it may be tempting to speculate that stratification
of antigenicity in nevi is related to neural differentiation, the lesional cells in
our study for the most part did not exhibit prominent neurotization. Like
others [36,37], we would favor the hypothesis that the findings reflect lesser
proliferative or functional activity of the deeper cells, a process that could be
more akin to senescence or atrophy than to differentiation. ‘‘Maturation,’’
defined as diminishing cell size, is an important histologic diagnostic criterion
for Spitz nevi. In a study of nuclear DNA content by LeBoit and Van Fletcher,
the superficial cells of Spitz nevi were more likely to be hyperdiploid,
whereas the deeper cells were diploid, a finding consistent with the notion
that maturation reflects lesser cell proliferation [6]. In the study of antigen
distribution reported here, however, Spitz nevi more closely resembled
melanomas than compound nevi.
The antibodies ME491, 506, 404, and NKI/C3 appear to recognize closely
related or identical antigens, and their reactivity was generally similar in this
study. The ME491 antigen was first characterized by Atkinson et al [23] as a
30–60-kDa highly glycosylated protein. It appears to be identical to CD63, an
activated platelet antigen that is also present on monocytes, macrophages,
some T and B lymphocytes, and granulocytes and is located within
melanosomal and lysosomal membranes [25]. The gene has been mapped
to chromosome 12 [38]. The antigen is homologous to TAPA-1, a
transmembrane protein that may have a role in cell proliferation and whose
gene has been localized to chromosome lip [39]. The NKI/C3 antigen was
described by van Duinen et al [27] and by MacKie et al [19] as a
heterogeneous 25–110-kDa glycoprotein present on the inner side of
melanoma cytoplasmic vesicles. There may be homology to the ME491
antigen. The antibodies ME491 and NKI/C3 have been shown to bind to other
tissue types, such as gastrointestinal and lung carcinomas, as well as some
benign epithelia. Although the antigen of ME67-6 is biochemically quite
different from that of ME491, its distribution was similar in the lesions studied.
The antigens recognized by antibodies ME491, NKI/C3, 506, 404, and ME67-
6 are highly conserved throughout the categories of pigmented lesions
studied, and all are excellent markers for neoplastic melanocytic cells in
paraffin sections with low to absent binding to other normal structures in
the skin.
There does not appear to be a clinical correlate for the finding that Spitz
nevi tend to be intermediate in antigenic reactivity and distribution between
compound nevi and melanoma. They do not display borderline malignant
behavior and recur no more frequently than common nevi when incompletely
excised [40]. Our findings suggest that antigenicity in Spitz nevi parallels their
histologic appearance that simulates melanoma but not their clinical
behavior. One might speculate that some of the associations reported here
might correlate with the property of invasiveness shared by Spitz nevi and
melanomas, whereas some other differences might correlate with the property
of ‘‘maturation’’ shared by common nevi and Spitz nevi. This property of
‘‘maturation’’ could represent a form of differentiation or a phenomenon more
closely related to senescence or atrophy. We are currently evaluating this
antibody panel on a series of dysplastic nevi and superficial spreading
melanomas.
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